Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests".

6/14/2024, 8:05 AM
Referred to the House Committee on Energy and Commerce.
Bill 118 hjres 145 is a piece of legislation that aims to disapprove of a rule submitted by the Food and Drug Administration (FDA) regarding "Medical Devices; Laboratory Developed Tests." The rule in question falls under chapter 8 of title 5, United States Code, which governs the regulatory process for federal agencies.

The bill seeks to exercise congressional oversight by disapproving of the FDA's rule, which likely means that Congress believes the rule is not in the best interest of the public or is not in line with congressional intent. The rule in question likely pertains to the regulation of laboratory developed tests, which are medical tests developed and performed within a single laboratory.

If this bill is passed, it would prevent the FDA from implementing the rule and would send a message that Congress does not support the FDA's approach to regulating laboratory developed tests. This could have significant implications for the FDA's ability to regulate medical devices and tests in the future. Overall, Bill 118 hjres 145 represents a significant moment in the ongoing debate over the regulation of medical devices and tests in the United States. It highlights the tension between congressional oversight and agency authority, and could have far-reaching implications for the FDA's regulatory powers.
Congress
118

Number
HJRES - 145

Introduced on
2024-05-16

# Amendments
0

Sponsors
+5

Cosponsors
+5

Variations and Revisions

5/16/2024

Status of Legislation

Bill Introduced
Introduced to House
House to Vote
Introduced to Senate
Senate to Vote

Purpose and Summary

Referred to the House Committee on Energy and Commerce.
Bill 118 hjres 145 is a piece of legislation that aims to disapprove of a rule submitted by the Food and Drug Administration (FDA) regarding "Medical Devices; Laboratory Developed Tests." The rule in question falls under chapter 8 of title 5, United States Code, which governs the regulatory process for federal agencies.

The bill seeks to exercise congressional oversight by disapproving of the FDA's rule, which likely means that Congress believes the rule is not in the best interest of the public or is not in line with congressional intent. The rule in question likely pertains to the regulation of laboratory developed tests, which are medical tests developed and performed within a single laboratory.

If this bill is passed, it would prevent the FDA from implementing the rule and would send a message that Congress does not support the FDA's approach to regulating laboratory developed tests. This could have significant implications for the FDA's ability to regulate medical devices and tests in the future. Overall, Bill 118 hjres 145 represents a significant moment in the ongoing debate over the regulation of medical devices and tests in the United States. It highlights the tension between congressional oversight and agency authority, and could have far-reaching implications for the FDA's regulatory powers.
Alternative Names
Official Title as IntroducedProviding for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests".

Policy Areas
Health

Comments

Recent Activity

Latest Action5/16/2024
Referred to the House Committee on Energy and Commerce.